OraSure Technologies, Inc. $OSUR Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 16.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,081,523 shares of the medical instruments supplier’s stock after selling 423,601 shares during the quarter. American Century Companies Inc. owned about 2.85% of OraSure Technologies worth $6,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC purchased a new stake in shares of OraSure Technologies during the second quarter worth about $26,000. Nierenberg Investment Management Company Inc. purchased a new position in shares of OraSure Technologies during the second quarter valued at approximately $35,000. Amundi acquired a new stake in OraSure Technologies during the first quarter worth approximately $47,000. Quantbot Technologies LP purchased a new stake in OraSure Technologies in the 1st quarter worth approximately $52,000. Finally, Envestnet Asset Management Inc. grew its stake in OraSure Technologies by 32.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 8,133 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR opened at $2.49 on Friday. The business has a 50-day moving average of $2.71 and a two-hundred day moving average of $2.93. The firm has a market capitalization of $178.62 million, a PE ratio of -3.11 and a beta of 0.75. OraSure Technologies, Inc. has a 12 month low of $2.08 and a 12 month high of $4.22.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 5th. The medical instruments supplier reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. OraSure Technologies had a negative return on equity of 13.61% and a negative net margin of 47.92%.The business had revenue of $27.09 million for the quarter, compared to analyst estimates of $28.96 million. As a group, research analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on OSUR. Stephens reduced their price target on OraSure Technologies from $3.50 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OraSure Technologies has a consensus rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.